APP Variant Profiling for Precise Alzheimer's Diagnosis and Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for accurately diagnosing and treating diseases characterized by unwanted accumulation of amyloid beta protein, such as Alzheimer's disease, due to the lack of effective tools for identifying and targeting non-classical variants of the amyloid beta precursor protein (APP) gene.
Innovation Solution
The methods involve measuring and comparing the expression or activity profiles of non-classical variants of the APP gene using long-read sequencing and specific probes, followed by administering agents that inhibit the activity of these variants to treat the associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If long-read sequencing and specific probes are used to measure expression profiles of non-classical APP variants, then diagnostic precision is improved, but device complexity and cost increase
Solution Approach 1:
The patent segments the APP gene analysis into distinct classical and non-classical variants, using specific probes designed to detect only non-classical variants. This segmentation allows precise measurement of the target variants without interference from classical variants, resolving the contradiction by focusing diagnostic precision on the specific pathological forms while managing complexity through targeted detection.
Solution Approach 2:
The patent introduces specific probes as intermediary molecules that bind to non-classical APP variants. These probes act as mediators between the sequencing technology and the target variants, enabling precise detection while simplifying the overall diagnostic process by providing a specific binding interface that reduces background noise and off-target effects.
2Reliability
If inhibitors targeting non-classical APP variants are administered, then treatment effectiveness is improved, but potential off-target effects and safety risks worsen
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular structures that recognize and bind only to unique features of non-classical APP variants. This specificity ensures that the treatment effect is localized to the pathological variants while leaving classical variants and other proteins unaffected, thereby improving treatment effectiveness while minimizing off-target effects.
Solution Approach 2:
Instead of trying to enhance the activity of protective classical variants, the patent inverts the approach by specifically inhibiting the harmful non-classical variants. This inversion strategy allows for more selective treatment with fewer off-target effects, as the inhibitors are designed to bind only to the pathological forms of the protein.
3Loss of information
If comprehensive expression profiling of all APP variants is performed, then complete disease characterization is improved, but measurement time and resource consumption worsen
Solution Approach 1:
The patent extracts and focuses specifically on measuring non-classical APP variants using targeted probes and optimized sequencing approaches. By extracting only the relevant information needed for diagnosis and treatment monitoring, the method achieves complete disease characterization for the pathological forms without the time and resource burden of profiling all APP variants.
Solution Approach 2:
The patent applies partial action by measuring only the non-classical variants that are directly relevant to disease pathogenesis and treatment response. This partial measurement approach provides sufficient information for complete disease characterization in the context of Alzheimer's therapy, while significantly reducing measurement time and resource consumption compared to comprehensive profiling of all APP variants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise identification and targeted treatment of diseases like Alzheimer's by inhibiting non-classical variants of the APP gene, thereby reducing amyloid beta protein accumulation.
Implementation Method 1
measuring the expression profile by a method comprising long-read sequencing of the biological sample from the individual
Implementation Method 2
measuring the expression profile comprises a method comprising binding of one or more probe(s) to the one or more non-classical variant(s)
Implementation Method 3
administering to the individual an agent that inhibits activity of one or more non-classical variant(s) of the APP gene
Data Source
AI summary
Described herein are methods for identifying and measuring one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing and treating an individual having or suspected of having Alzheimer's disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s).